Literature DB >> 19575614

Stress hormone regulation: biological role and translation into therapy.

Florian Holsboer1, Marcus Ising.   

Abstract

Stress is defined as a state of perturbed homeostasis following endangerment that evokes manifold adaptive reactions, which are summarized as the stress response. In the case of mental stress, the adaptive response follows the perception of endangerment. Different peptides, steroids, and biogenic amines operate the stress response within the brain and also after they have been released into circulation. We focus in this review on the biological roles of corticosteroids, corticotrophin-releasing hormone (CRH), and arginine vasopressin (AVP), and we evaluate the effects of treatments directed against the actions of these hormones. CRH and AVP are the central drivers of the stress hormone system, but they also act as neuromodulators in the brain, affecting higher mental functions including emotion, cognition, and behavior. When released toward the pituitary, these central neuropeptides elicit corticotrophin into the periphery, which activates corticosteroid release from the adrenal cortex. These stress hormones are essential for the adequate adaptation to stress, but they can also evoke severe clinical conditions once persistently hypersecreted. Depression and anxiety disorders are prominent examples of stress-related disorders associated with an impaired regulation of stress hormones. We summarize the effects of drugs acting at specific targets of the stress hormone axis, and we discuss their potential use as next-generation antidepressant medications. Such treatments require the identification of patients that will optimally benefit from such specific interventions. These could be a first step into personalized medicine using treatments tailored to the specific pathology of the patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19575614     DOI: 10.1146/annurev.psych.093008.100321

Source DB:  PubMed          Journal:  Annu Rev Psychol        ISSN: 0066-4308            Impact factor:   24.137


  104 in total

1.  [The future of depression research].

Authors:  F Holsboer
Journal:  Nervenarzt       Date:  2010-11       Impact factor: 1.214

Review 2.  Neurobiology of chronic mild stress: parallels to major depression.

Authors:  Matthew N Hill; Kim G C Hellemans; Pamela Verma; Boris B Gorzalka; Joanne Weinberg
Journal:  Neurosci Biobehav Rev       Date:  2012-07-07       Impact factor: 8.989

Review 3.  Evidence for the role of corticotropin-releasing factor in major depressive disorder.

Authors:  R Parrish Waters; Marion Rivalan; D A Bangasser; J M Deussing; M Ising; S K Wood; F Holsboer; Cliff H Summers
Journal:  Neurosci Biobehav Rev       Date:  2015-08-10       Impact factor: 8.989

Review 4.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

5.  Cortisol, oxytocin, and quality of life in major depressive disorder.

Authors:  Ai Ling Tang; Susan J Thomas; Theresa Larkin
Journal:  Qual Life Res       Date:  2019-06-21       Impact factor: 4.147

6.  Animal models of depression: molecular perspectives.

Authors:  Vaishnav Krishnan; Eric J Nestler
Journal:  Curr Top Behav Neurosci       Date:  2011

Review 7.  Don't stress about CRF: assessing the translational failures of CRF1antagonists.

Authors:  Samantha R Spierling; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

8.  Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression.

Authors:  Clarissa D Staton; Jazmine D W Yaeger; Delan Khalid; Fadi Haroun; Belissa S Fernandez; Jessica S Fernandez; Bali K Summers; Tangi R Summers; Monica Sathyanesan; Samuel S Newton; Cliff H Summers
Journal:  Neuropharmacology       Date:  2018-09-18       Impact factor: 5.250

Review 9.  [Depression and neurological diseases].

Authors:  D Piber; K Hinkelmann; S M Gold; C Heesen; C Spitzer; M Endres; C Otte
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

10.  Overexpression of CRF in the BNST diminishes dysphoria but not anxiety-like behavior in nicotine withdrawing rats.

Authors:  Xiaoli Qi; Lidia Guzhva; Zhihui Yang; Marcelo Febo; Zhiying Shan; Kevin K W Wang; Adriaan W Bruijnzeel
Journal:  Eur Neuropsychopharmacol       Date:  2016-07-22       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.